N-tert-butoxycarbonylamino-O-pyridin-3-ylmethyl-D-serine | 872413-80-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tert-butoxycarbonylamino-O-pyridin-3-ylmethyl-D-serine
• 英文别名: (2R)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(pyridin-3-ylmethoxy)propanoic acid
• CAS: 872413-80-4
• 化学式: C₁₄H₂₀N₂O₅
• 分子量: 296.323
• InChiKey: RCEMOXHMZKUFOQ-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  97.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-tert-butoxycarbonylamino-O-pyridin-3-ylmethyl-D-serine 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 醋酸异丙酯 、 水 为溶剂， 生成
  参考文献：
  名称：

  Structure activity studies of the serine-AIB dipeptide domain in 2,3-dihydroisothiazole based growth hormone secretagogues

  摘要：

  A series of growth hormone secretagogues (GHSs) based on 2,3-dihydroisothiazole has been synthesized in the search for a potential treatment of growth hormone deficiency or frailty in the elderly. This paper describes the evaluation of the SAR of the benzyl-D-Ser-aminoisobutyric acid dipeptide fragment. Introduction of substituents in the peptide backbone and in the phenyl ring has been investigated, as well as replacements for the benzyl group and for the AIB residue. A number of modifications resulted in enhanced potency over the parent benzyl-D-Ser-AIB derivative. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.070
• 作为产物：
  描述：

  3-溴甲基吡啶 、 BOC-D-丝氨酸 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以67%的产率得到N-tert-butoxycarbonylamino-O-pyridin-3-ylmethyl-D-serine
  参考文献：
  名称：

  Structure activity studies of the serine-AIB dipeptide domain in 2,3-dihydroisothiazole based growth hormone secretagogues

  摘要：

  A series of growth hormone secretagogues (GHSs) based on 2,3-dihydroisothiazole has been synthesized in the search for a potential treatment of growth hormone deficiency or frailty in the elderly. This paper describes the evaluation of the SAR of the benzyl-D-Ser-aminoisobutyric acid dipeptide fragment. Introduction of substituents in the peptide backbone and in the phenyl ring has been investigated, as well as replacements for the benzyl group and for the AIB residue. A number of modifications resulted in enhanced potency over the parent benzyl-D-Ser-AIB derivative. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.07.070

文献信息

• 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS
  申请人：Ambarkhane Ameet Vijay

  公开号：US20120302540A1

  公开（公告）日：2012-11-29

  The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a disorder or a disease mediated by the ghrelin receptor.

  该发明涉及公式（I）的衍生物，其中取代基如规范中定义；制备这种衍生物的过程；包含这种衍生物的药物组合物；将这种衍生物作为药物；将这种衍生物用于治疗由胃泌素受体介导的疾病或障碍。
• 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists
  申请人：Ambarkhane Ameet Vijay

  公开号：US20130331369A1

  公开（公告）日：2013-12-12

  The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a disorder or a disease mediated by the ghrelin receptor.

  本发明涉及公式（I）的衍生物，其中取代基如规范中所定义；制备此类衍生物的过程；包括此类衍生物的制药组合物；此类衍生物作为药物；此类衍生物用于治疗由胃饥饿素受体介导的紊乱或疾病。
• L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5]DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS
  申请人：Novartis AG

  公开号：EP2852591A1

  公开（公告）日：2015-04-01
• US8546416B2
  申请人：——

  公开号：US8546416B2

  公开（公告）日：2013-10-01
• [EN] 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE 3-SPIROCYCLIQUE COMME AGONISTES DU RÉCEPTEUR DE LA GHRÉLINE
  申请人：NOVARTIS AG

  公开号：WO2012164473A1

  公开（公告）日：2012-12-06

  The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a disorder or a disease mediated by the ghrelin receptor.